Acurian Saves Four Months of Enrollment Time for a Type 1 Diabetes Study

Endocrinology

Type 1 Diabetes

A leading company in diabetes began phase III studies with the goal of expanding its portfolio with a next-generation basal insulin analog.

Read More »